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pEVICE RECALLS
he paper with the most far-reaching ramifications in the
eld of device therapy in 2005 was not published in any
cientific journal but by an investigative reporter in the New
ork Times on May 24, 2005 (1). The article reported that
21-year-old patient with hypertrophic cardiomyopathy
nd an implantable cardioverter-defibrillator (ICD) had
ied suddenly. Analysis of the explanted ICD (a Guidant
861 Ventak Prizm 2, Guidant, Indianapolis, Indiana)
howed that a catastrophic device failure had occurred.
hen the device attempted to deliver a shock in the
resence of ventricular tachyarrhythmia, electrical arcing
ccurred in the device header, resulting in a short-circuit
ith extensive damage to the generator integrated circuit,
nd no shock therapy was delivered to treat the fatal
entricular arrhythmia. Two months later, the physicians
nvolved published their account in the journal Heart
hythm (2). This was then followed by commentaries in the
ew England Journal of Medicine (3) and Circulation (4) and
ore articles on related issues in the New York Times (5–8).
ne of the many issues and questions raised in these articles
s whether it was appropriate for Guidant officials not to
nform the physicians of a potentially fatal flaw in its 1861
entak Prizm 2 ICD, of which they had known since
ebruary 2002 and for which changes in the manufacturing
rocess had been made twice, in 2002. By not reporting the
roblem to the physicians, as pointed out by Hauser and
aron, Guidant had in effect assumed an unprecedented
ole in managing the patients (4). The authors also ques-
ioned the effectiveness of the Food and Drug Administra-
ion (FDA) in monitoring the safety of market release
edical devices, especially low-frequency, device failures.
Since February 2005, several major ICD and pacemaker
ecalls, safety alerts, and advisories have been issued by
edtronic (Minneapolis, Minnesota) (9), Guidant (10–15),
nd St. Jude Medical (St. Paul, Minnesota) (16). In response
o the Guidant controversies, the Heart Rhythm Society
nd the FDA co-sponsored a one-day Policy Conference on
evice performance to discuss the current state of device
echnology, surveillance, and communications on product
erformance among industry, the FDA, and health care
roviders (17). Several areas requiring improvement have
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Manuscript received December 7, 2005; accepted December 21, 2005.een identified. The FDA seeks to increase the ability of its
enter for Devices and Radiological Health (CDRH) to
evelop active surveillance and identification of medical
evice failure and to improve communication between the
DA, manufacturers, physicians, and the public. Changes
eing considered include creation of an electronic database
ystem for adverse event reporting that would allow faster,
ore critical evaluation of data by CDRH, allocation of
ore resources to target quality assurance, and development
nd improvement of guidelines for adverse-events reporting
y manufacturers and for the FDA review of post-
arketing changes to devices.
At the same conference, Maisel (18) presented some
isquieting data on the reliability of ICDs. The author
eviewed device malfunctioning reports filed with the FDA
rom 1990 to 2002 by manufacturers of pacemakers and
CDs. Eighty percent of malfunctions were due to hardware
roblems (electrical, battery/capacitor, connector/header,
harge circuit, and hermetic seal). The malfunction replace-
ent rate for ICDs was much higher than that of pacemak-
rs (the overall replacement rates for pacemaker and ICD
ere 5 and 21 per 1,000 devices, respectively). During the
tudy period, the rate of ICD malfunctions followed a
imodal pattern. The replacement rate for malfunction first
eaked at about 39 per 1,000 devices in 1993, which was
ollowed by a sharp drop to about 11 in 1994. From 1994 to
998, the malfunction rate remained stable at about 8 to 9
er 1,000. It then increased rapidly to a peak of about 36 per
,000 in 2001. The report found that 50% of the defibril-
ator malfunctions had occurred in the last 3 years of the
tudy (2000 to 2002). It has been speculated that the drive to
iniaturize defibrillators might be a factor in the growing rate
f malfunctions; however, because the time from implant to
ailure was not reported, the higher failure rate in 2001 could
ave occurred in larger devices implanted in the late 1990s.
ore aggressive reporting of malfunction and replacement
f devices might have attributed to the upward trend, as
uggested by the author. After reaching a peak in 2001, the
alfunction replacement rate dropped from 39 to 22 per
,000 in 2002. Inclusion of data from 2002 to 2004 would
rovide a better picture of recent trending. Many malfunc-
ions have lesser clinical impact than others. Most impor-
antly, the report serves to provide us with a time-line of
evice performance. We will have a more informative
icture only after we achieve better and more standardized
eporting protocols and detailed analysis of data.
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The Year in Clinical Electrophysiology March 21, 2006:1207–13One of the repercussions of the recalls is that the number
f device alerts, advisories, and recalls will predictably
ncrease, because the bar for identifying device adverse
vents will be set very low. The physicians might be
urdened with information overload. It is therefore impor-
ant for the FDA, manufacturers, and professional societies
o work together to provide the practicing physicians with
ore defined practice guidelines to handle the reported
evice failures.
CD THERAPY
he much-anticipated results of the Sudden Cardiac Death
n Heart Failure Trial (SCD-HeFT) were published in
anuary 2005 (19). This trial examined whether amiodarone
r ICD reduced all-cause mortality compared with placebo
n patients with either left ventricular ejection fraction
LVEF) 0.35 or heart failure due to ischemic or non-
schemic dilated cardiomyopathy. When compared with
lacebo, amiodarone did not improve survival, but ICD
educed mortality by 23%. The reduction was observed in
oth the ischemic (hazard ratio [HR]  0.79) and the
on-ischemic group (HR  0.73), regardless of QRS
uration. An interesting finding is that patients with New
ork Heart Association (NYHA) functional class II seemed
o benefit more from ICD therapy than patients with more
evere heart failure. The defibrillation testing protocol at the
ime of implantation was intriguing. If a 30-J ICD shock
highest deliverable energy) failed to restore sinus rhythm,
o further testing or lead repositioning would be attempted.
he device was implanted and the patient enrolled in the
tudy. It is not known how many such patients were
ncluded in the study and how successful their ICDs were in
reating clinical tachyarrhythmias during the follow-up
eriod. If the number of patients was high and their
utcome was similar to those with lower (20-J or lower)
efibrillation testing threshold, one can postulate that defi-
rillation testing might not be necessary at the time of
mplant. This would greatly simplify the implantation
rotocol. The results of DEFibrillators In Non-Ischemic
ardiomyopathy Treatment Evaluation (DEFINITE) and
CD-HeFT argue strongly for implantation of an ICD in
atients with non-ischemic dilated cardiomyopathy with
educed LVEF and moderate heart failure (NYHA func-
ional class II and III) for mortality benefits. As a result
f these studies, the Centers for Medicare & Medicaid
ervices (CMS) broadened the coverage for ICD implan-
ation (20).
In 2004, 135,000 ICDs were implanted in the U.S.,
ccounting for $3.5 billion in sales. With expanding indi-
ations for ICD implantation, the numbers of implantations
re expected to increase to as high as 500,000 (21). The
ost-effectiveness of ICDs becomes an increasingly signifi-
ant health economic issue. This was analyzed by using a
ecision model to estimate costs and survival among
atients who received either an ICD for the primary erevention of sudden death or control therapy (22). The
ealth and economic outcomes of the prophylactic im-
lantation of an ICD as compared with control therapy
ere computed for the eight published ICD primary
revention trials (MADIT-I, CABG Patch, MUSTT,
ADIT-II, DEFINITE, DINAMIT, COMPANION,
CD-HeFT). The authors found that the cost-effectiveness
f the ICD in the six patient cohorts where survival benefit
as demonstrated ranged from $34,000 (MUSTT) to
70,200 (SCD-HeFT) per quality-adjusted life-year gained
CABG Patch and DINAMIT were excluded in this
nalysis because these two studies showed no survival
enefit). The authors reported that in appropriately selected
atients, the incremental cost-effectiveness of ICDs is
imilar to that of other interventions often accepted as
ost-effective. It is apparent from the modeling that by using
lower-cost ICD with a longer battery life in high-risk
atients, we can reduce the cost per quality-adjusted life-
ear gain. It is obvious that better risk stratification of
atients will allow us to better target our therapy and lower
xpenditures. As a very first step in an attempt to improve
evice use, CMS now mandates registering of ICDs and
linical data of patients under Medicare coverage with the
CD Registry of the American College of Cardiology-
ational Cardiovascular Data Registry (ACC-NCDR)
23). Furthermore, remote full-disclosure device monitoring
ill also provide reliable active surveillance. The data will
llow us to perform longitudinal analysis to measure device
erformance, clinical outcomes, and to refine risk stratifica-
ion for better use of our health dollars.
ARDIAC RESYNCHRONIZATION THERAPY (CRT)
he benefits of CRT in heart failure were further demon-
trated by the results of the Cardiac Resynchronization-
eart Failure (CARE-HF) trial (24). Patients with NYHA
unctional class III and IV heart failure from non-ischemic
nd ischemic cardiomyopathy, LVEF 0.35, left ventricu-
ar end-diastolic dimension 30 mm, and QRS duration
120 ms were randomized to receive medical therapy alone
r with cardiac resynchronization (biventricular pacing ther-
py). The primary end point was the time to death from any
ause or an unplanned hospital stay for a major cardiovas-
ular event. The secondary end point was overall mortality.
uring the mean follow-up period of 29.4 months, there
ere significantly more patients in the medical-therapy
roup reaching the primary end point than in the CRT
roup (39% vs. 55%; HR, 0.64). Overall mortality was
ignificantly lower in the CRT group (20% vs. 30%; HR,
.64). The beneficial effects of CRT in this group of
atients were impressive, considering that these patients
ere receiving optimal medical therapy with diuretics,
eta-blockers, spironolactone, angiotensin-converting en-
yme inhibitor, or angiotensin-receptor blocker at the time
f the enrollment. Strikingly, the results showed that for
very nine devices implanted, one death and three hospital
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March 21, 2006:1207–13 The Year in Clinical Electrophysiologytays were prevented (for comparison, it was 18 for 1 life
aved in MADIT-II). These very favorable results for CRT
aise the question of whether inclusion of defibrillation
herapy will add any significant mortality benefit. It has
een recently shown that in MADIT-II patients, among
ther events, worsening heart failure, increasing blood urea
itrogen, and NYHA class II were associated with an
ncreased risk for ICD therapy for ventricular tachycardia/
entricular fibrillation (VT/VF) and death (25). By revers-
ng ventricular remodeling, CRT provides an added theo-
etical benefit over ICD by favorably modifying the
ubstrate for arrhythmogenesis to prevent VT/VF (26). We
ave no knowledge, however, of the time line for achieving
uch theoretical benefit; 7% of the CRT group died sud-
enly, which could have been prevented by defibrillation.
urther investigation on the relationship between reverse
emodeling by CRT and arrhythmias will be very rewarding
n our understanding of mechanisms of arrhythmogenesis
nd allocation of resources in treatment of heart failure.
ACEMAKERS
ven as we are well into the fifth decade of pacing for
radycardia, the controversy over single-chamber versus
ual-chamber pacing has yet to be settled. This controversy
as re-examined in patients with high-grade atrioventricu-
ar block in the United Kingdom Pacing and Cardiovascular
vents Trial (UKPACE). In this trial patients were random-
zed to receive a single-chamber fixed rate ventricular
acemaker, single-chamber rate-adaptive pacemaker, or a
ual-chamber pacemaker. The average age was 80 years.
he primary end point was all-cause mortality with a
edian follow-up period of 4.6 years. Secondary end points
ncluded atrial fibrillation (AF), heart failure, and throm-
oembolic events with a median follow-up period of 3 years.
here were no significance differences in survival benefit
nd in the secondary end points between the single-
hamber groups and the dual-chamber group. With the
xception of AF, the findings are similar to the Canadian
rial Of Physiologic Pacing (CTOPP), which included
atients with sick sinus syndrome and atrioventricular block
27). Subgroup analysis showed that NYHA functional class
nd history of chronic heart failure did not affect the
rimary end point. This study provides a very strong
rgument for implantation of a single-chamber pacemaker
n elderly patients whose perception of quality of life is
robably different from the younger population. Despite
ecent publications supporting implantation of single-
hamber pacemakers and similar professional fee reimburse-
ent for single-chamber and dual-chamber pacemaker
mplantation, the percentage of dual chamber implants
emains at 80% (28,29). One can argue that if the adjusted
osts for a dual-chamber pacemaker over the lifetime of the
atient are comparable to those for a single-chamber pace-
aker, then the biggest reason for implanting the simpleringle-chamber pacemaker no long exits. This is the con- Alusion of a recent report on the analysis of the cost-
ffectiveness of these two pacing modes (30).
IOLOGY OF CARDIAC FIBRILLATION
ver the past 12 months, information related to the biology
f fibrillation—once almost always in the exclusive province
f the basic physiologist—has now shown signs of invading
he clinical domain. We have decided to briefly review this
nformation and describe the possible clinical links.
ecause the mechanism of both AF and VF seem to be
imilar, a more generic term “cardiac fibrillation” will be
sed.
It is now accepted that fibrillation is initiated by wave-
reak, the latter occurring when an emerging wave front
ncounters refractory tissue and splits into daughter waves
31). A number of important factors have been found to
nfluence the dynamics of wavebreak. These factors have
een separated into “functional factors,” action potential
uration (APD), and internal calcium (Ca) cycling or to
ifferences in tissue heterogeneity. Weiss et al. (32) have
opularized the designation of wavefront as phase O of the
PD and waveback as its termination (Fig. 1). Wavebreak
ccurs when the wave front collides with the waveback, and
f the break is spatially localized re-entry might result. This
ight occur around a fixed anatomic site or might produce
rotor (33). A rotor represents the three-dimensional
xpression of re-entry, and its physiology is best explained
y examination of the spiral wave that is the two-
imensional expression of the rotor or scroll wave (Fig. 2).
he scroll wave differs from anatomic re-entry because it is
erpetuated by a core of excitable but unexcited cells. The
egion adjacent to the core is exposed to large electrostatic
radients that serve to significantly shorten the APD. The
ncreased curvature of the leading edge of the spiral wave
eads to a decreased safety margin for conduction, causing
he wave to rotate around an anchor. Wavebreaks can
ccur in relationship to focal prolongation of refractori-
ess and/or altered conduction. These factors might be
ffected by tissue heterogeneity (infarction/scar) or by
rugs or ischemia (34,35).
Once a rotor is established it might become anchored to
specific site and produce a monomorphic arrhythmia or
ight prove to be unstable and break into numerous
aughter wavelets. Rotors might be thus characterized as
eing due to a dominant mother rotor with fibrillatory
onduction from a localized area, or rotors might meander
n time and space (36).
A powerful predictor of wave front instability is gleaned
rom analyses of the APD restitution relationship. The
PD or cardiac refractoriness will shorten in response to an
ncrease in the paced cardiac rate. Actually, the interval
etween the end of one action potential and beginning of
he next or diastolic interval (DI) determines the length of
PD. Pacing at short lengths produces a short DI (and
PD), and the restitution curve is characterized by the
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teep (i.e., 1), then small peturbations in DI will produce
arge changes in APD and will promote APD alternans
igure 1. The cardiac impulse as an electrical wave, with a wave front (bla
orresponding to repolarization. Wavelength () is the product of action pote
ith waveback instability due to APD local prolongation. (C) Wave with wa
igure 2. Action potential duration (APD) restitution slope and rotor sta
ecreases (computer simulation). (B) APD restitution curves, with slope
urrent). (C, D) Spiral wave behavior several seconds after initiating a rot
hallow (D) APD restitution slope. (E, F) Optically measured surface volta
locking the L-type calcium current with D600 (0.5 mg/ml) to flatten the APD
attern. In F, VF has converted to VT, manifested as a stable double-armed ro37,38). The alternans might be either concordant or
iscordant (opposite long-short dynamic between cells)
lternans. These states are highly arrhythmogenic as pre-
orresponding to the upstroke of the AP, and a waveback (gray to white),
uration (APD) and conduction velocity (CV). (A) Uniform wave. (B) Wave
nt instability due to local CV slowing. Reprinted from Weiss et al. (32).
. (A) APD shortening and APD alternans as pacing cycle length (PCL)
olid line) or 1 (dashed line, obtained with 50% block of the calcium
homogeneous 2D tissue. All cells are identical, with either a steep (C) or
aps in an intact Langendorff rabbit heart before (E) and after (F) partiallyck) cbility
1 (s
or in
ge mrestitution slope to 1. In E, multiple wave fronts move in a complex VF
tor. Reprinted from Weiss et al. (32).
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March 21, 2006:1207–13 The Year in Clinical Electrophysiologyature impulses emerging from cells with the short APD
eet refractory tissue in cells showing a long APD, thus
eading to wavebreak and fibrillation (39).
The important roles of changes in channel function
short-term memory) as well as with internal Ca flux are
eyond the scope of this review but are well described in a
ecent review article (40).
The preceding consideration explains the two dominant
heories related to the pathogenesis of fibrillation. One
osits the random collision of multiple co-existing wavelets
41), whereas the other suggests that fibrillation is driven by
focal source (rotor) (42). Others have shown, both in
nimal models as well as in dense atrial mapping studies of
atients in AF, evidence that suggest a dominant frequency
DF) detected by Fast-Fourier signal analyses of the fibril-
atory wave (42).
Use of DF mapping of humans during invasive clinical
tudies has recently been reported (43). These studies are
ased on the findings that rotor activity identified by optical
apping correlated with the DF found by signal analyses
36). Sanders et al. (44) studied 32 patients with either
ermanent or persistent AF with a system that allows for
etermination of Fast-Fourier signal analyses for patients with
F. They mapped 58 electrogram sequences from 126  13
ites from both the right and left atrium. Three-dimensional
aps were constructed on the bases of highest amplitude
requency analyses. The operators were unaware of the
ndings and used standard techniques for left atrial ablation.
he sites of ablation were correlated with regions of highest
F and change in AF cycle length and arrhythmia termi-
ation. They found that 13 of the 15 (87%) who had AF
ermination did so at DF sites. In addition, patients with
aroxysmal AF had more DF located within the pulmonary
eins whereas those with persistent AF more likely had
ther atrial sites. In summary, the technique described
nvolves a totally new approach for potential ablation of
atients with AF.
Lin et al. (45) nicely characterized the mechanism of AF
n a subgroup of patients with paroxysmal AF localized to
he right atrium. These authors used a non-contact map-
ing system during sinus rhythm, atrial pacing, or induced
F. They found channels through lines of block that acted
s mother rotors, which gave rise to daughter waves and
brillatory conduction. In addition, Fast-Fourier transform
nalyses allowed for identification of the sites of these
hannels. They found, as opposed to the usual findings, a
F gradient from right to left atrium (coronary sinus
eptum). Ablation lines directed at putative channel sites
esulted in acute success for 11 of 13 patients. This study
icely characterizes the pathogenesis of a unique form of
aroxysmal AF.
Everett et al. (46) used a non-contact mapping system to
xplore the mechanism of VF in canine models of heart
ailure. During VF, the DF was obtained with Fast-Fourier
ransform of signals derived from the ESI non-contact
apping system (Endocardial Solutions Inc., St. Paul, winnesota). Of interest was the finding that the mechanism
f VF (i.e., meandering, focal, or rotor activity) varied
epending on the etiology of the congestive heart failure. In
ontrol dogs subjected to VF, meandering rotors were
ound, whereas those with heart failure showed a stable
otor or focal source. Those with ischemia initially showed
focal source that became reentrant. These studies high-
ight the idea that fibrillation is not a totally random, chaotic
vent, and better understanding of underlying mechanism(s)
romises to allow for better treatment of fibrillation.
Another study that was directed toward application of
hese basic physiologic concepts was an innovative approach
o assess APD restitution curves in patients with heart
isease. Koller et al. (47) recorded monophasic action
otentials from a catheter in the right ventricular septum
oth in patients with normal hearts and in those with
tructural cardiac disease. The authors analyzed ventricular
PD restitution curves in response to overdrive pacing.
hey found that patients with structural cardiac disease had
wider DI, at which APD alternans was found. Even
hough the recordings were obtained from the right ventri-
le (in a group with predominant left ventricular dysfunc-
ion) the authors described a novel approach for assessment
f electrical stability and raise the idea that this approach
ight prove to be one alternative target for drug therapy.
NTIARRHYTHMIC DRUG THERAPY
here has been continued interest in the development and
tudy of new antiarrhythmic agents. Perhaps the closest
gent nearing FDA approval is Dronedarone (48). This is a
rug that is structurally similar to amiodarone (benzofurane
erivative) but without iodine. Amiodarone is the most
ffective drug available for treatment of patients with either
T or AF but its use is limited because of the frequency of
ide effects. Recent studies have corroborated the initial
esults of the DAFNE trials (48), which showed that
ronedarone was more effective than placebo for mainte-
ance of sinus rhythm after cardioversion. In addition, the
ajor toxicity proved to be gastrointestinal intolerance and
here were no reports of cardiac, hepatic, thyroid, or
ulmonary toxicity.
Another drug with interesting potential for acute cardio-
ersion of patients with AF is known as RSD1235. This
gent is both an atrio-selective potassium (K) channel
locker as well as a sodium (Na) channel blocker. Two
tudies have been published that explored the efficacy and
afety of this drug. Roy et al. (49) showed that AF
erminated in 61% of patients treated with this drug without
ignificant adverse effects. Similar results are reported at the
ate-breaking trials of the Heart Rhythm Society (May
005) (50). In this larger trial including 221 patients treated
ith drugs, conversion to sinus rhythm occurred in 52%,
gain with minimal side effects (transient alteration in taste).
he initial reports using RSD1235 seem to compare well
ith other agents (ibutilide, flecainide) used for acute conver-
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The Year in Clinical Electrophysiology March 21, 2006:1207–13ion to sinus rhythm. The favorable side effects are especially
oteworthy.
Singh et al. (51) reported the results of a large-scale,
andomized, double-blinded Veteran’s Administration hos-
ital study comparing the efficacy of amiodarone, sotalol,
nd placebo for both conversion and maintenance of sinus
hythm in patients with AF. They found that both amio-
arone (27.1%) and sotalol (24.2%) had similar conversion
ates but that amiodarone was statistically superior to sotalol
n maintenance of sinus rhythm after external cardioversion.
trial fibrillation recurred over a mean of 487, 209, and 13
ays (amiodarone, sotalol, and placebo, respectively).
In a follow-up substudy from the same group (52), the
atients who maintained sinus rhythm had better quality of life
cores compared with those who reverted to AF. The latter
nding seems to contradict the initial findings of the AFFIRM
rial but is probably closer to our clinical experience.
ENETIC DISORDERS
everal notable advances have been made in the realm of the
nherited channelopathies. Probably the most important is
iscovery of the genetic mutation causing Timothy’s syn-
rome (53). This syndrome was initially reported in chil-
ren with multisystem disorders and sudden death due to
ardiac arrhythmia. The disorder results from a missense
utation (G406R) of the gene encoding the calcium chan-
el Cav1.2, owing to loss of inward Ca inactivation.
he cardiac arrhythmias are attributed to Ca overload
tate. The authors recently reported an expanded series
ncluding 21 phenotyped patients (54). The median age at
eath was 33 months and the electrocardiogram showed a
ean corrected QT interval of 600 ms with a pattern similar
o that described for the Long QT3 syndrome (prolonged
T-segment with normal T-wave). Timothy’s syndrome has
een designated as the LQT8 syndrome.
There continues to be great interest in the genetic analysis
f patients with arrhythmogenic right ventricular dysplasia
ARVD). This is a fascinating cardiomyopathy that affects
he right ventricle (and left ventricle with time) and is
ssociated with sudden death due to ventricular arrhythmia.
n the past, only a small number of patients were found to
ave abnormalities in genes encoding the adherens or
esmosome proteins. These proteins are responsible for
aintenance of the cytoskeletal structure of the heart.
bnormalities of the genes encoding plakoglobin (Naxos
isease) and desmoplakin (Caravajal syndrome) were re-
orted earlier. More recently, mutations in plakophilin have
een found responsible for approximately 30% of the ge-
etic mutations for patients with ARVD (55). An excellent
ummary of the genetics of this disorder was recently
ublished (56).
ATHETER ABLATION
here is continued interest in the growing field of catheter
blation for cure of AF. Over the past year interest has beenocused both on the traditional methods of pulmonary vein
solation and wide area left atrial ablation. The newer
pproaches involve better understanding of the relationship
f fractionated electrograms (57) with left atrial gangli-
nated plexes (58). Vagal denervation was found by Lemery
t al. (59) to be associated with excellent short-term success
n patients with AF.
A most interesting study by Haissaguerre et al. (60)
nvolved use of ablative procedures for 60 patients with
hronic AF. Successful ablation in patients with chronic AF
as proved particularly difficult to achieve. The French
roup used both pulmonary vein isolation, together with
esion across the left atrial roof and mitral isthmus (from the
eft inferior pulmonary vein to the mitral annulus), as well as
blation of fractionated electrograms and reported an 82%
hort-term success. The report offers new hope for expan-
ion of ablative procedures to the chronic group. This
rocedure is, however, lengthy and involves numerous
blative lesions; hence, caution must be used in wider
pplication of this approach.
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